Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including SARS-CoV-2.
Lactiga has earned awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
Lactiga has earned awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
Location: United States, New Jersey
Employees: 1-10
Total raised: $1.6M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Checkmate ... | checkmatec... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.09.2022 | Pre-Seed | $1.6M | - |
Mentions in press and media 5
| Date | Title | Description |
| 23.01.2023 | CSIT Awards $1.275 Million to 17 New Jersey Startups Focused on Supporting Maternal & Infant Health | First Lady Tammy Murphy (immediately left of podium) poses with NJEDA CEO Tim Sullivan (behind podium), CSIT Executive Director Judith Sheft (far right), CSIT staff and grant program awardees. “New Jersey is home to some of the most innovat... |
| 22.09.2022 | Lactiga Therapeutics Raises USD$1.6M Pre-Seed Funding | Lactiga Therapeutics, a North Brunswick, NJ- and Toronto, Canada-based biotechnology company, raised USD$1.6m in Pre Seed funding including over $350k in research grants. The round was led by 1517 Fund. In addition to the capital raised, th... |
| 21.09.2022 | Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants | NORTH BRUNSWICK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Lactiga Therapeutics, an early-stage biotechnology company focused on improving the quality of life of patients with primary immunodeficiency diseases, announced this week that it ha... |
| 21.09.2022 | Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants | /EIN News/ -- NORTH BRUNSWICK, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Lactiga Therapeutics, an early-stage biotechnology company focused on improving the quality of life of patients with primary immunodeficiency diseases, announced this w... |
| - | Lactiga | “Lactiga™ is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlock... |